arrow
S

Si Shi

fudan university shanghai cancer center
H指数:58
被引数:1.4万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

A phase 1 trial of APG-1387, an IAP antagonist, with nab-paclitaxel and gemcitabine in patients with refractory metastatic pancreatic cancer

一项关于APG-1387(一种IAP拮抗剂)联合nab-紫杉醇和吉西他滨治疗难治性转移性胰腺癌的Ⅰ期临床试验

2025-09-190
OAAI
Phase 1b study of first-line fuzuloparib combined with modified FOLFIRINOX followed by fuzuloparib maintenance monotherapy in pancreatic adenocarcinoma (vol 22, 365, 2024)

胰腺腺癌中,将fuzuloparib联合改良FOLFIRINOX作为一线治疗,随后进行fuzuloparib维持单药治疗的Phase 1b研究(卷22,365,2024)

2025-04-140
OA